Brain Health & Nootropics
PE-22-28
← Back to Library
Limited / unverified Limited / unverified Limited / unverified Neural Antidepressant
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 10 mg
Dosing window: Morning
Receptor / target: TREK-1
Properties: Neural Stimulant
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 400mcg to 800mcg daily | Administer subQ in the morning. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative: Split Dosing
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 200mcg twice daily | Used by researchers who experience a mid-afternoon crash from a single morning bolus. Administered AM and early afternoon. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 50 mcg 1x Daily | |
| Weeks 3-4 | 100 mcg 1x Daily | |
| Weeks 5-8 | 100 mcg 1x Daily | |
| Weeks 9-12 | 150 mcg 1x Daily | |
| Weeks 13-16 | 200 mcg 1x Daily |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Nootropic protocols are state-dependent: sleep, anxiety, stimulants, psychiatric history, and route can change the response. The logic is morning-biased, low-entry dosing, and stopping if arousal or mood destabilizes. Entry context: target (TREK-1); route Subcutaneous; timing Morning. Limited-evidence dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Bipolar disorder (any phase): TREK-1 antagonism increases neuronal excitability and monoaminergic tone; in subjects with bipolar disorder, this mechanism can trigger manic switch: the same class risk that makes antidepressant monotherapy hazardous in bipolar; absolute contraindication without mood stabilizer coverage and clinical supervision. Limited / unverified
- Active manic or hypomanic episode: TREK-1 blockade-driven neuronal disinhibition would directly accelerate the hyperexcitable, elevated monoamine state of mania. Limited / unverified
- Known hypersensitivity to PE-22-28, spadin-derived peptides, or formulation excipients. Limited / unverified
- Concurrent use with MAO inhibitors: TREK-1 antagonism increases serotonin and norepinephrine availability by disinhibiting raphe and locus coeruleus neurons; combined with MAO inhibition this produces dangerous monoamine excess; serotonin syndrome risk. Limited / unverified
- Concurrent use with other serotonergic agents (SSRIs, SNRIs, triptans, tramadol, linezolid): additive serotonergic activity; monitor for serotonin syndrome symptoms (hyperthermia, clonus, agitation, diaphoresis). Limited / unverified
- Severe cardiovascular disease with arrhythmia: TREK-1 is expressed in cardiac tissue where it contributes to action potential repolarization; blockade of cardiac TREK-1 could affect cardiac rhythm at high doses. Limited / unverified
- Pregnancy: no safety data; neuronal excitability modulation during fetal brain development is not established as safe. Limited / unverified
- Breastfeeding: no safety data. Limited / unverified
- Pediatric use: TREK-1 plays developmental roles in the maturing CNS; PE-22-28 use in pediatric subjects is not established as safe. Limited / unverified
Side effects (limited evidence)
- Overstimulation and nervous energy: the most dose-dependent adverse effect; TREK-1 blockade-driven neuronal disinhibition at higher doses produces a heightened CNS excitability state characterized by restlessness, racing thoughts, and inability to wind down; managed by strict morning administration and dose reduction. Limited / unverified
- Headache: one of the most commonly reported adverse effects; neuronal excitability increase and monoamine elevation produce cerebrovascular effects that manifest as headache, particularly in the first 1-2 weeks; typically self-limiting. Limited / unverified
- Insomnia: evening or late afternoon administration of PE-22-28 produces predictable sleep onset difficulty from the neuronal excitability and monoamine elevation effects; strict morning dosing mitigates. Limited / unverified
- Mid-afternoon energy crash: reported in subjects using a single morning bolus dose; as PE-22-28 clears, the TREK-1 rebound may produce a brief period of fatigue; the split-dose alternative protocol (AM + early afternoon) was developed specifically to manage this. Limited / unverified
- Mild anxiety: paradoxical given the antidepressant intent; neuronal hyperexcitability from TREK-1 blockade in anxiety-circuit neurons (amygdala, anterior cingulate) can produce anxious arousal alongside the antidepressant activity; Selank co-administration is the standard mitigation strategy. Limited / unverified
- Nausea: uncommon; mild; reported in the first week of use. Limited / unverified
- Injection site irritation: mild redness and soreness at the subcutaneous administration site. Limited / unverified
- Palpitations: rare; TREK-1 is expressed in cardiac tissue; at higher doses, cardiac TREK-1 blockade may produce subjective palpitation awareness; not typically clinically significant in healthy subjects. Limited / unverified
- No SSRI-class adverse effects: PE-22-28 does not block SERT, NET, or any reuptake transporter; it produces no sexual dysfunction, weight gain, emotional blunting, or discontinuation syndrome characteristic of SSRI/SNRI therapy. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.